LABORIE completed its acquisition of Unisensor AG and Unisensor USA, Inc. Unisensor is headquartered in Wiesendangen, Switzerland with US operations in Portsmouth, New Hampshire. Unisensor specializes in the development and manufacture of micro, high resolution sensors to measure pressure and pH values for the Gastroenterology and Urology markets.
LABORIE’s acquisition of Unisensor extends its innovation and market leadership in Urology diagnostic pressure measurement to the Gastroenterology market. Unisensor will remain a standalone GI platform with R&D and manufacturing continuing in Wiesendangen and Portsmouth along with a continued focus on the existing customer channel.
“We are very excited about the combination of Unisensor and LABORIE,” stated Brian Ellacott, LABORIE President and CEO. “Both companies have a history of innovation in our respective markets and there is a tremendous opportunity to leverage these technologies in the adjacent Urology and GI diagnostic and treatment markets.”
Unisensor CEO, Peter Schlumpf stated, “We are very pleased to be part of the Laborie team with its global reputation as an innovation leader in pelvic floor diagnostics and treatment. The common philosophy and culture in technology development between our two organizations and will allow us to bring exciting new products at a faster pace to the Urology and Gastroenterology markets.”
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in the UK at NHS Trust on June 11, 2021 by Dr. Pareeta Patel and Professor. Nick Watkin.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in Mannheim, Germany on January 22, 2021 by Dr. Georgi Tosev (Mannheim Urology).
Transaction demonstrates LABORIE’s commitment to providing innovative solutions to urologists globally LABORIE to invest $15 million in Urotronic Series C financing LABORIE secures option to acquire Urotronic’s Optilume™ technology